Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high70.32 17/02/17
52 week low31.44 09/11/16
52 week change 13.00 (33.77%)
4 week volume4,433,591 31/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Preparation of Lupuzor'sT Regulatory Submissions

RNS Number: 7616R Immupharma PLC 26 September 2017 RNS: FOR IMMEDIATE RELEASE 26 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") ImmuPharma initiates preparation of Lupuzor's regulatory submissions ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to confirm a furthe...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3535R Immupharma PLC 21 September 2017 21 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

ImmuPharma schedules interims

ImmuPharma, the specialist drug discovery and development company, has confirmed that it would announce its results f...

Notification of Interim Results

RNS Number: 0613R Immupharma PLC 19 September 2017 FOR IMMEDIATE RELEASE 19 SEPTEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") NOTIFICATION OF INTERIM RESULTS Date: 27 September 2017 ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, confirms that it will be announcing it...

AIM Rule 17 Notice

RNS Number: 4650O Immupharma PLC 18 August 2017 18 August 2017 ImmuPharma Plc AIM Rule 17 Notice ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedu...

Grant of Options

RNS Number: 8456K Immupharma PLC 12 July 2017 12 July 2017 Grant of Options ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over 1,40 0,000 ordinary shares of 10p each ("Ordinary Shares") to certain of its non-executive Directors repr...

Result of AGM

RNS Number: 7583J Immupharma PLC 30 June 2017 FOR IMMEDIATE RELEASE 30 JUNE 2017 2017 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all res...

Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLC

Northland Capital today reaffirms its buy investment rating on ImmuPharma PLC (LON:IMM) and raised its price targe...

Fundamental DataMore

EPS-4.54
Dividend yield0 %

Latest discussion posts More

  • Immupharma

    Immupharma caught my attention two years ago. I have a substantial holding below the current price. The main development is the Lupus drug now in its final stage of testing. ...
    31-Aug-2017
    Didledum
  • This one caught my attention

    Taking a closer look When is the next announcement? End of September?
    31-Aug-2017
    Aberdeen_investor
  • Re: 9.5% rise...

    Topped @ 49.25p ..10.06
    6-Jun-2017
    Ripley94

Users' HoldingsMore

Users who hold Immupharma also hold..
LLOYDS GRP.29%
BP20%
SIRIUS MINERALS14%
NATIONAL GRID13%
LEGAL&GEN.12%

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM